AVEO is a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology and other novel targeted combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the company.

https://www.aveooncology.com/

AVEO Pharmaceuticals

LG Chem Ltd is a Korea-based company principally engaged in the manufacture of petrochemical materials. The company operates its business through five segments, providing a range of chemicals and materials for various industries including electronics, automotive, and pharmaceuticals.

https://www.lgchem.com/

LG Chem  Ltd

LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) and AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced today that they have entered into a definitive agreement under which LG Chem will acquire AVEO for $15.00 per share in an all-cash transaction with an implied equity value of $566 million on a fully diluted basis.

Lg Chem To Acquire Aveo Oncology For $15.00 Per Share In Cash

Lg Chem To Acquire Aveo Oncology For $15.00 Per Share In Cash

Company Info